Leukemia Drug Boosts Endocrine Breast Tx (CME/CE)
SAN ANTONIO (MedPage Today) -- The leukemia drug dasatinib (Sprycel) doubled time to disease progression or death for women starting hormonal therapy for metastatic breast cancer but failed to affect clinical response, an early-phase trial showed.
Source: MedPage Today OB/GYN - Category: OBGYN Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | Hormonal Therapy | Hormones | Leukemia | OBGYN | Women